The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary glucose excretion. The physiologic response to pharmacologically induced acute or chronic glycosuria has not been investigated in human diabetes. METHODS: We evaluated 66 patients with type 2 diabetes (62 ± 7 years, BMI = 31.6 ± 4.6 kg/m(2), HbA1c = 55 ± 8 mmol/mol, mean ± SD) at baseline, after a single dose, and following 4-week treatment with empagliflozin (25 mg). At each time point, patients received a mixed meal coupled with dual-tracer glucose administration and indirect calorimetry. RESULTS: Both single-dose and chronic empagliflozin treatment caused glycosuria during fasting (median, 7.8 [interquartile range {IQR}, 4.4] g/3 hours and 9.2 [IQR, 5.2] g/3 hours) and after meal ingestion (median, 29.0 [IQR, 12.5] g/5 hours and 28.2 [IQR, 15.4] g/5 hours). After 3 hours of fasting, endogenous glucose production (EGP) was increased 25%, while glycemia was 0.9 ± 0.7 mmol/l lower (P < 0.0001 vs. baseline). After meal ingestion, glucose and insulin AUC decreased, whereas the glucagon response increased (all P < 0.001). While oral glucose appearance was unchanged, EGP was increased (median, 40 [IQR, 14] g and 37 [IQR, 11] g vs. 34 [IQR, 11] g, both P < 0.01). Tissue glucose disposal was reduced (median, 75 [IQR, 16] g and 70 [IQR, 21] g vs. 93 [IQR, 18] g, P < 0.0001), due to a decrease in both glucose oxidation and nonoxidative glucose disposal, with a concomitant rise in lipid oxidation after chronic administration (all P < 0.01). β Cell glucose sensitivity increased (median, 55 [IQR, 35] pmol • min(-1) • m(-2) • mM(-1) and 55 [IQR, 39] pmol • min(-1) • m(-2) • mM(-1) vs. 44 [IQR, 32] pmol • min(-1) • m(-2) • mM(-1), P < 0.0001), and insulin sensitivity was improved. Resting energy expenditure rates and those after meal ingestion were unchanged. CONCLUSIONS: In patients with type 2 diabetes, empagliflozin-induced glycosuria improved β cell function and insulin sensitivity, despite the fall in insulin secretion and tissue glucose disposal and the rise in EGP after one dose, thereby lowering fasting and postprandial glycemia. Chronic dosing shifted substrate utilization from carbohydrate to lipid. Trial registration. ClinicalTrials.Gov NCT01248364 (EudraCT no. 2010-018708-99). Funding. This study was funded by Boehringer Ingelheim.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous RCTs reported that selective SGLT2 inhibitors, a new class of anti-diabetes drugs, have been shown to reduce body weight (1–3 kg reduction) in diabetic patients with and without obesity [99–102].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,604
Self-citationWatson, P. E., Watson, I. D., & Rd, B. (1980) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/33.1.27 · Cited by 1,477
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Effect of fatty acids on glucose production and utilization in man.
Ferrannini, E., Barrett, E. J., Bevilacqua, S., & DeFronzo, R. A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111133 · Cited by 1,050
Self-citationINDOCYANINE GREEN: OBSERVATIONS ON ITS PHYSICAL PROPERTIES, PLASMA DECAY, AND HEPATIC EXTRACTION*
Cherrick, G. R., Stein, S. W., Leevy, C. M., & Davidson, C. S. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104072 · Cited by 978
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 887
Rossetti, L., Smith, D. J., Shulman, G. I., Papachristou, D. N., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 824
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Vallon, V., Platt, K. A., Cunard, R. A., Schroth, J., Whaley, J. M., Thomson, S. C., Koepsell, H., & Rieg, T. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010030246 · Cited by 565
Bolinder, J., Ljunggren, Ö., Johansson, L. O. M., Wilding, J. P. H., Langkilde, A., Sjöström, C. D., Sugg, J. E., & Parikh, S. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 492
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 466
Self-citationHabib, A. M., Richards, P., Cairns, L. S., Rogers, G. J., Bannon, C. A. M., Parker, H. E., Morley, T. C. E., Yeo, G. S. H., Reimann, F. M., & Gribble, F. M. (2012) · Endocrinology · doi:10.1210/en.2011-2170 · Cited by 382
Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Gastaldelli, A., Baldi, S., Pettiti, M., Toschi, E., Camastra, S., Natali, A., Landau, B. R., & Ferrannini, E. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1367 · Cited by 320
Self-citationThe disposal of an oral glucose load in patients with non-insulin-dependent diabetes
Ferrannini, E., Simonson, D. C., Katz, L. D., Reichard, G., Bevilacqua, S., Barrett, E. J., Olsson, M., & DeFronzo, R. A. (1988) · Metabolism · doi:10.1016/0026-0495(88)90033-9 · Cited by 305
Self-citationInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303
Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects
Mari, A., Schmitz, O., Gastaldelli, A., Oestergaard, T., Nyholm, B., & Ferrannini, E. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00093.2002 · Cited by 303
Self-citationHeise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., SEMAN, L. J., & Woerle, H. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12073 · Cited by 277
Self-citationGlucose transport by human renal Na + / d -glucose cotransporters SGLT1 and SGLT2
Hummel, C. S., Lü, C., Loo, D. D. F., Hirayama, B. A., Voss, A. A., & Wright, E. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00388.2010 · Cited by 273
Polidori, D., Sha, S., Mudaliar, S. R. D., Ciaraldi, T. P., Ghosh, A., Vaccaro, N. M., Farrell, K., Rothenberg, P., & Henry, R. R. (2013) · Diabetes Care · doi:10.2337/dc12-2391 · Cited by 264
Zambrowicz, B., Freiman, J., Brown, P., Frazier, K., Turnage, A., Bronner, J., Ruff, D. S., Shadoan, M. K., Banks, P. L., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 251
Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
Liu, J., Lee, T. W., & DeFronzo, R. A. (2012) · Diabetes · doi:10.2337/db12-0052 · Cited by 227
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Jurczak, M. J., Lee, H., Birkenfeld, A. L., Jornayvaz, F. R., Frederick, D. W., Pongratz, R. L., Zhao, X., Moeckel, G. W., Samuel, V. T., Whaley, J. M., et al. (2011) · Diabetes · doi:10.2337/db10-1328 · Cited by 221
Devineni, D., Curtin, C. R., Polidori, D., Gutierrez, M. J., Murphy, J., Rusch, S., & Rothenberg, P. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.88 · Cited by 216
Habib, A. M., Richards, P., Rogers, G. J., Reimann, F. M., & Gribble, F. M. (2013) · Diabetologia · doi:10.1007/s00125-013-2887-z · Cited by 184
Dose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach
Natali, A., Gastaldelli, A., Camastra, S., Sironi, A. M., Toschi, E., Masoni, A., Ferrannini, E., & Mari, A. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.5.e794 · Cited by 112
Self-citationMechanisms for abnormal postprandial glucose metabolism in type 2 diabetes
Woerle, H. J., Szoke, E., Meyer, C., Dostou, J. M., Wittlin, S. D., Gosmanov, N. R., Welle, S. L., & Gerich, J. E. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00529.2004 · Cited by 109
Self-citationCamastra, S., Muscelli, E., Gastaldelli, A., Holst, J. J., Astiarraga, B., Baldi, S., Nannipieri, M., Ciociaro, D., Anselmino, M., Mari, A., et al. (2013) · Diabetes · doi:10.2337/db13-0321 · Cited by 106
Self-citationMechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
Muscelli, E., Casolaro, A., Gastaldelli, A., Mari, A., Seghieri, G., Astiarraga, B., Chen, Y., Alba, M., Holst, J. J., & Ferrannini, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1205 · Cited by 102
Self-citationPlosker, G. L. (2012) · Drugs · doi:10.2165/11209910-000000000-00000 · Cited by 99
Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting
Calado, J., Loeffler, J., Sakallıoğlu, O., Gök, F., Lhotta, K., Barata, J. D., & Rueff, J. (2006) · Kidney International · doi:10.1038/sj.ki.5000194 · Cited by 99
Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms
Bonuccelli, S., Muscelli, E., Gastaldelli, A., Barsotti, E., Astiarraga, B., Holst, J. J., Mari, A., & Ferrannini, E. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00127.2009 · Cited by 90
Self-citationNilsson, O., Bilchik, A. J., Goldenring, J. R., Ballantyne, G. H., Adrian, T. E., & Modlin, I. M. (1991) · Endocrinology · doi:10.1210/endo-129-1-139 · Cited by 88
on behalf of the RISC Investigators, Ferrannini, E., Natali, A., Muscelli, E., Nilsson, P. M., Golay, A., Laakso, M., Beck-Nielsen, H., & Mari, A. (2011) · Diabetologia · doi:10.1007/s00125-011-2112-x · Cited by 80
Self-citationKinetics of glucagon in man: effects of starvation.
Fisher, M., Sherwin, R. S., Hendler, R., & Felig, P. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.5.1735 · Cited by 78
Sugar uptake into brush border vesicles from normal human kidney.
Turner, R. J., & Silverman, M. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.7.2825 · Cited by 74
Nicolaus, M., Brödl, J., Linke, R., Woerle, H., Göke, B., & Schirra, J. R. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0841 · Cited by 73
Self-citationEffect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes
Gastaldelli, A., Casolaro, A., Pettiti, M., Nannipieri, M., Ciociaro, D., Frascerra, S., Buzzigoli, E., Baldi, S., Mari, A., & Ferrannini, E. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100034 · Cited by 68
Self-citationMari, A., Stojanovska, L., Proietto, J., & Thorburn, A. W. (2002) · Computer Methods and Programs in Biomedicine · doi:10.1016/s0169-2607(02)00097-4 · Cited by 56
Self-citationMari, A., Wahren, J., DeFronzo, R. A., & Ferrannini, E. (1994) · Metabolism · doi:10.1016/0026-0495(94)90038-8 · Cited by 55
Self-citationNagata, T., Fukazawa, M., Honda, K., Yata, T., Kawai, M., Yamane, M., Murao, N., Yamaguchi, K., Kato, M., Mitsui, T., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2012 · Cited by 45
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.12089fp · Cited by 36
Familial renal glucosuria: a clinicogenetic study of 23 additional cases
Lee, H.-K., Han, K. H., Park, H. W., Shin, J. I., Kim, C. J., Namgung, M. K., Kim, K. H., Koo, J. W., Chung, W. Y., Lee, D., et al. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2109-9 · Cited by 33
Dapagliflozin: a review on efficacy, clinical effectiveness and safety
Paisley, A. N., Yadav, R., Younis, N., Rao‐Balakrishna, P., & Soran, H. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.740009 · Cited by 27
TAYLOR, H. L., & Tiede, K. (1952) · Journal of Clinical Investigation · doi:10.1172/jci102594 · Cited by 25
Flagged first, then by citations
Research works printed but not linked: 1
- Yki-Järvinen, 1992, Endocr Rev., 13, 415
Cited by
Sorted by citations
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationMulti-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Puchalska, P., & Crawford, P. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.022 · Cited by 1,682
“…sodium/glucose cotransporter 2 (SGLT2i) increases circulating ketone body concentrations in humans (Ferrannini et al., 2016a; Inagaki et al., 2015) and mice (Suzuki et al., 2014) via increased hepatic ketogenesis (Ferrannini et al., 2014, 2016a; Katz and Leiter, 2015; Mudaliar et al., 2015).”
BackgroundCV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
“The subtraction of large amounts of glucose from the glucose pool, coupled with the dual hormonal changes, results in a 25% restriction of glucose utilization, and a concomitant increase in lipid mobilization and usage for energy production (24).”
BackgroundSelf-citationFitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Self-citationMechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 941
Metadata
- Authors
- Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J.
- Affiliations
- University of Pisa (IT)
- National Research Council (IT)
- Profil Institute for Metabolic Research (DE)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 499-508
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3904627
- OpenAlex
- W2157405334
- Cited by
- 1,134
- References
- 45
- Citations by year
- 2026: 55 · 2025: 68 · 2024: 80 · 2023: 81 · 2022: 92 · 2021: 117 · 2020: 106 · 2019: 103 · 2018: 97 · 2017: 90 · 2016: 121 · 2015: 83 · 2014: 39
- FWCI
- 89.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Novo Nordisk
- Astellas Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- SGLT2 inhibitors, empagliflozin, type 2 diabetes, glycosuria, endogenous glucose production, glucose oxidation, nonoxidative glucose disposal, lipid oxidation, beta-cell glucose sensitivity, glucagon response, insulin response, glucose metabolism, indirect calorimetry, mixed meal tolerance, urinary glucose excretion, glucose homeostasis
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Blood Glucose, Calorimetry, Diabetes Mellitus, Type 2, Female, Glucose, Glucosides, Glycosuria, Glycated Hemoglobin, Humans, Insulin, Male, Metformin, Middle Aged, Oxygen, Body Mass Index, Postprandial Period, Area Under Curve, Insulin-Secreting Cells, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
